CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2020—SeraCare Life Sciences launched genomic DNA and formalin-fixed, paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. SeraCare collaborated with Friends of Cancer Research and International Quality Network for Pathology in the development and evaluation of a range of gDNA and FFPE-based TMB reference materials across different targeted NGS panels, sequencing platforms, and bioinformatics analysis pipelines.
Pages: 1 2